Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Marky1 on Mar 30, 2021 9:59pm

IPO

The original IPO was was June 18 th 2013....It began trading at the equivalent price of $5.50 (.55$ presplit).  That's almost 8 years of no movement of the SP...Our long voyage is about to break out, IMHO.
The way I see things going...Further partnership deals with pharm companies such as GUD for Latin America, other deals for the USA, Europe, Japan and the rest of the world...Money swelling up our chest...
Final dissolution of ANTIBE Holding Corporation leading to one strong and uncomplicated entity.
By August, 7 months after hiring Dr. Haut, i believe that he will present to the world a huge acquisition deal with Bayer for the entire company. It took him exactly 7 months to ink a deal to sell the company that he was working for ( AskBio) for 4B$ USD
people..hang on to your shares...worth their weight in gold !

Exciting days are coming..
Comment by JimmyJ on Mar 30, 2021 10:55pm
Correct me if I'm wrong, I don't believe Don Haut is leading the negotiations onbehalf of Antibe.  Don was appointed to the Partnering Advisory Team, which is not a full time gig.  My guess is the team meets with Dan and the ATE leadership team periodically to discuss strategy, open doors, set up connections etc.  Not trying to burst your bubble here Marky, I like your ...more  
Comment by MrMugsy on Mar 31, 2021 10:39am
You could be right JimmyJ ... might be a weekly meeting with Dan - but - I don't know the details of the team make-up. Marky is excited about the $4B deal with AskBio and he's hoping Don has the right skills and connections to get us to the promised land. A little too early to call the end game (if there is an end game) - but I'm sure they're working on potential partnering.  ...more  
Comment by bringon10bagger on Mar 31, 2021 7:32pm
This hardly seems reasonable based on the Nuance deal, 100M overall for 10% of market share for Otena, prorating entire MS to be worth 1B, certainly seems on low side for potential sales of 4B annually and 21B by 2034, in just US, EU, and Japan......am I missing something here?? 
Comment by MrMugsy on Mar 31, 2021 10:09pm
Yes ... I agree that it's on the low side. But ... China wasn't on anyone's radar and the deal became a cheap win for Nuance and it put cash in the bank for ATE.  A win-win at the right time for us.  We know that this gets more expensive going forward.   ----- (Also ... not just the $ but the value of the royalties)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities